Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

October 31, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

Trial Locations (16)

10003

Beth Israel Med. Ctr., ACTU, New York

10016

NY Univ. HIV/AIDS CRS, New York

14607

AIDS Care CRS, Rochester

14642

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

Univ. of Pennsylvania Health System, Presbyterian Med. Ctr., Philadelphia

27599

Unc Aids Crs, Chapel Hill

35294

Alabama Therapeutics CRS, Birmingham

43210

The Ohio State University Medical Center, Columbus

44106

Case CRS, Cleveland

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

63110

Washington U CRS, St Louis

90095

UCLA CARE Center CRS, Los Angeles

94110

Ucsf Aids Crs, San Francisco

98104

University of Washington AIDS CRS, Seattle

02906

The Miriam Hosp. ACTG CRS, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00011011 - Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV | Biotech Hunter | Biotech Hunter